Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Policy & Acquisitions

Mergers & Acquisitions

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Mergers & Acquisitions

214 stories · every one Fact-Checked
Jazz Pharmaceuticals to acquire Actio Biosciences for ABS-1230 KCNT1 epilepsy therapyMergers & AcquisitionsJazz Pharmaceuticals to Acquire Actio Biosciences to Expand Rare Epilepsy PortfolioJazz Pharmaceuticals will acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent payments, gaining ABS-1230, an investigational oral KCNT1 inhibitor being developed for…11 Aug 2026 · 3 min read
Fact-Checked
Soligenix discontinues HyBryte development after Phase 3 FLASH2 trial halted for futility in cutaneous T-cell lymphomaMergers & AcquisitionsSobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphomaSobi and Innate Pharma partner to advance lacutamab in T-cell lymphoma, with TELLOMAK-3 Phase 3 designed to support potential accelerated…10 Aug 2026 · 4 min read
Fact-Checked
BeOne Medicines and Revolution Medicines RAS(ON) inhibitor collaboration for RAS-driven cancerMergers & AcquisitionsBeOne, Revolution Medicines Expand RAS(ON) Cancer Collaboration in AsiaBeOne Medicines and Revolution Medicines will evaluate combinations of BeOne oncology assets with four RAS(ON) inhibitors while expanding development and commercialization rights across selected Asian markets.10 Aug 2026 · 3 min read
Fact-Checked
Evotec and Odyssey Therapeutics announce strategic AI-driven drug discovery collaboration to develop novel small molecule therapies for autoimmune and inflammatory diseases.Mergers & AcquisitionsEvotec, Odyssey Partner to Advance AI-Driven Small Molecule Discovery for Autoimmune and Inflammatory DiseasesEvotec and Odyssey Therapeutics have formed a strategic collaboration to discover AI-enabled small molecule therapies for autoimmune and inflammatory diseases…7 Aug 2026 · 3 min read
Fact-Checked
Illustration of antibody therapeutics targeting activated myofibroblasts in fibro-inflammatory diseases under the Ono Pharmaceutical and Mediar Therapeutics research collaboration.Mergers & AcquisitionsOno and Mediar Partner to Develop Novel Antibody Therapies for FibrosisOno Pharmaceutical and Mediar Therapeutics have entered a discovery collaboration to develop novel antibody therapeutics targeting myofibroblasts for fibro-inflammatory diseases.7 Aug 2026 · 3 min read
Fact-Checked
FUJIFILM Corporation and Taiho Pharmaceutical partner to develop next-generation antibody-drug conjugate (ADC) manufacturing technologies using the AraLinQ platform.ManufacturingFujifilm, Taiho Partner to Advance Manufacturing of Next-Gen ADCsFUJIFILM Corporation and Taiho Pharmaceutical have formed a strategic partnership to optimize manufacturing technologies for next-generation antibody-drug conjugates using the AraLinQ platform, strengthening global ADC production capabilities.5 Aug 2026 · 3 min read
Fact-Checked
Evexta Bio and Roche collaboration for rupitasertib and giredestrant combination in ESR1-mutated breast cancer trialMergers & AcquisitionsEvexta Bio and Roche Partner on Phase 1b Trial of Rupitasertib Plus Giredestrant in ESR1-Mutated Advanced Breast CancerEvexta Bio has signed a clinical collaboration and supply agreement with Roche to evaluate the all-oral combination of rupitasertib (a dual-node PAM pathway inhibitor) and giredestrant (an oral…4 Aug 2026 · 3 min read
Fact-Checked
Tinlarebant receives FDA Priority Review for Stargardt Disease Type 1Clinical TrialsAmplia and Lilly Partner to Advance Narmafotinib Plus Olomorasib for KRAS G12C-Mutant NSCLCAmplia Therapeutics has entered a clinical trial collaboration with Eli Lilly to evaluate the combination of the investigational FAK inhibitor narmafotinib and the KRAS G12C inhibitor olomorasib in…4 Aug 2026 · 3 min read
Fact-Checked
Illustration of multispecific T-cell engager antibodies targeting immune cells, representing the AbCellera and Vertex Pharmaceuticals collaboration to develop novel therapies for autoimmune diseases.Mergers & AcquisitionsAbCellera, Vertex Sign Deal to Develop Autoimmune T-Cell EngagersAbCellera and Vertex Pharmaceuticals have formed a strategic collaboration to develop multispecific T-cell engagers for autoimmune diseases and other conditions.31 Jul 2026 · 3 min read
Fact-Checked
McKesson to acquire Precision Medicine Group for $2.25 billion to expand clinical research and biopharma commercialization servicesMergers & AcquisitionsRelation, GSK Partner in $110M AI Drug Discovery CollaborationRelation and GSK have formed a strategic collaboration worth up to $110 million to generate large-scale human cellular perturbation datasets that will train AI foundation models, including MORGAN…31 Jul 2026 · 3 min read
Fact-Checked
MBX Biosciences once-weekly canvuparatide enters Phase 3 oPTimize trial for chronic hypoparathyroidismMergers & AcquisitionsJohnson & Johnson Partners with Sail Biomedicines for In Vivo CAR-T TherapiesJohnson & Johnson has entered a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases.30 Jul 2026 · 3 min read
Fact-Checked
ANDEMBRY (garadacimab-gxii) Phase 3b study demonstrated positive safety and attack prevention results in children aged 2 to 11 years with hereditary angioedema (HAE).Mergers & AcquisitionsCSL Reports Positive Phase 3b Results for ANDEMBRY in Children With HAECSL reported positive Phase 3b topline results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema.28 Jul 2026 · 4 min read
Fact-Checked
Page 6 of 18